Bristol-Myers Squibb Co (BMY)

Add to Watchlists
Create an Alert
Quickflows
59.72 -0.09  -0.15% NYSE May 29, 20:00 Delayed 2m USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All BMY News

News

View All Events

Events

Date Type Description
07/24/2020 10:30 EDT Misc Bristol-Myers Squibb Co Second Quarter Earnings Conference Call in 2020
07/24/2020 Earnings Bristol-Myers Squibb Co Second Quarter Earnings in 2020 Release
05/07/2020 08:30 EDT Misc Bristol-Myers Squibb Co First Quarter Earnings Conference Call for 2020
05/07/2020 Earnings Bristol-Myers Squibb Co First Quarter Earnings Result for 2020
05/05/2020 Misc Bristol-Myers Squibb Co Annual General Meeting for 2019
04/02/2020 Dividends Amount: 0.45, Declared Date: Mar 02 2020, Pay Date: May 01 2020
02/24/2020 Misc Bristol-Myers Squibb Co Annual Report for 2019
02/06/2020 08:30 EST Misc Bristol-Myers Squibb Co Fourth Quarter Earnings Conference Call for 2019
02/06/2020 Earnings Bristol-Myers Squibb Co Fourth Quarter Earnings in 2019 Release
01/02/2020 Dividends Amount: 0.45, Declared Date: Dec 05 2019, Pay Date: Feb 03 2020
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 31.01B
Total Expenses (TTM) 26.03B
Net Income (TTM) 954.00M

Balance Sheet View Statement

Total Assets (Quarterly) 129.28B
Total Liabilities (Quarterly) 79.31B
Shareholders Equity (Quarterly) 49.91B

Cash Flow Statement View Statement

Cash from Operations (TTM) 10.57B
Cash from Investing (TTM) -10.18B
Cash from Financing (TTM) 8.596B

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.bms.com
  • Investor Relations URL: N/A
  • HQ State/Province: New York
  • Sector: Healthcare
  • Industry: Drug Manufacturers - General
  • Equity Style: Large Cap/Blend
  • Next Earnings Release: Jul. 24, 2020
  • Last Earnings Release: May. 07, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: Apr. 02, 2020
  • Description: Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 59.72
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
VGHCX Vanguard Health Care Inv 5.01%
SCHD Schwab US Dividend Equity ETF™ 4.40%
LBFAX Loomis Sayles Bond Admin 3.76%
XLV Health Care Select Sector SPDR® ETF 3.63%
VHCIX Vanguard Health Care Index Admiral 3.25%
VHT Vanguard Health Care ETF 3.25%
OIEFX JPMorgan Equity Income R2 2.61%
DODGX Dodge & Cox Stock 2.27%
MTUM iShares Edge MSCI USA Momentum Fctr ETF 2.00%
VHYAX Vanguard High Dividend Yield Index Adm 1.46%
VYM Vanguard High Dividend Yield ETF 1.46%
DGRO iShares Core Dividend Growth ETF 1.18%

Comparables

Edit
AMGN Amgen Inc
BIIB Biogen Inc
GILD Gilead Sciences Inc
JNJ Johnson & Johnson
LLY Eli Lilly and Co

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.